Compositions and methods for treating retinal degradation

Patent metadata

Field	Value
Publication number	US-12097201-B2
Application number	US-202418439523-A
Country	US
Kind code	B2
Filing date	Feb 12, 2024
Priority date	Feb 26, 2015
Publication date	Sep 24, 2024
Grant date	Sep 24, 2024

Abstract

The present disclosure relates to modified nucleoside reverse transcriptase inhibitors (NRTIs), such as

and compositions thereof, as well as methods useful for treating retinal damage and/or retinal degradation/retinal degeneration, for inhibiting inflammasome activation by Alu RNA associated with a cell, for reducing ATP-induced permeability of a cell, for reducing an amount of mitochondrial reactive oxygen species in a cell, and for reducing an amount of mitochondrial reactive oxygen species in a cell. The present disclosure further relates to modified NRTIs and compositions thereof, as well as methods for use in protecting an RPE cell and/or for treating, including prophylactic and therapeutic treatment, of conditions associated with retinal damage and/or degradation including, but not limited to, dry age related macular degeneration (AMD) and wet AMD, Alzheimer disease, various forms of arthritis, atherosclerosis, diabetes mellitus, chronic obstructive pulmonary disease, inflammatory bowel disease, and Duchenne muscular dystrophy.

First claim

What is claimed is:

1. A compound selected from:

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , wherein the compound is selected from:

or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1 , wherein the compound is selected from:

or a pharmaceutically acceptable salt thereof.

4. The compound of claim 1 , wherein the compound is selected from:

or a pharmaceutically acceptable salt thereof.

5. The compound of claim 4 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

6. A pharmaceutical composition comprising a compound selected from:

or a pharmaceutically acceptable salt thereof.

7. The composition of claim 6 , wherein the compound is selected from:

or a pharmaceutically acceptable salt thereof.

8. The composition of claim 6 , wherein the compound is selected from:

or a pharmaceutically acceptable salt thereof.

9. The composition of claim 6 , wherein the compound is selected from:

or a pharmaceutically acceptable salt thereof.

10. The composition of claim 6 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

Assignees

• Univ Kentucky Res Found

Inventors

• Ambati Jayakrishna
• Fowler Benjamin
• Ambati Kameshwari

Classifications

• C07D411/04

  directly linked by a ring-member-to-ring-member bond · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A61P25/16

  Anti-Parkinson drugs · CPC title

• Y02A50/30

  Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title

• A61K31/506 Primary

  not condensed and containing further heterocyclic rings · CPC title